We develop and supply generic, biosimilar, innovative and over-the-counter healthcare products as well as finished doses and active pharmaceutical ingredients (API).

In 2021, we issued a $5B sustainability-linked bond (SLB)—the largest of its kind when it was issued and the first from a generic medicines company – with leading target of promoting Access to medicines. Teva committed to bringing more medicines to emerging economies to treat non-communicable diseases (NCDs) and increasing regulatory submissions and products on the WHO’s EML across six key TAs, provided to vulnerable populations through new programs in LMICs. In 2023, Teva issued an additional SLB valued at $2.5B, with the same Access to medicines targets. This demonstrates how integral Access is to our business model.

The six TAs in focus are cardiovascular diseases; Adult and pediatric oncology; Respiratory diseases; Diabetes; Mental health and pain/palliative care.

In 2021, we committed to launch eight access to medicines programs by 2025. As of 2022, we launched five of these programs, providing treatments to vulnerable populations across the globe through customized, localized models.